Amgen Inc
NASDAQ:AMGN

  • LAST PRICE
    325.2800
  • TODAY'S CHANGE (%)
    3.3700 (1.0469%)
  • Bid / Lots
    323.6200/ 1
  • Ask / Lots
    327.8900/ 1
  • Open / Previous Close
    322.4800 / 321.9100
  • Day Range
    321.2800
    328.2500
  • 52 Week Range
    260.5200
    346.8500
  • Volume
    1,978,146

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

      Show headlines and story abstract

    • 9 hours ago by PR Newswire
      Companies Mentioned: AMGN

      Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday, Nov. 13, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

    • 9 hours ago by Dow Jones
      Companies Mentioned: AMGN

      AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE

      PR Newswire

      THOUSAND OAKS, Calif., Nov. 8, 2024

      THOUSAND OAKS, Calif., Nov. 8, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday, Nov. 13, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

    • 20 hours ago by MT Newswires
      Companies Mentioned: AMGN, AZN
      04:54 AM EST, 11/08/2024 (MT Newswires) -- Amgen (AMGN) said late Thursday that its drug, Tezspire, which it co-developed with AstraZeneca (AZN) to treat patients with chronic rhinosinusitis with nasal polyps, met primary goals in a phase 3 study. T...

    • 23 hours ago by PR Newswire
      Companies Mentioned: AMGN

      Statistically Significant Reduction in Nasal Polyp Size, Nasal Congestion Compared to Placebo

      Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial demonstrated patients treated with TEZSPIRE(R) (tezepelumab-ekko) had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. The safety profile and tolerability ofTEZSPIREin the trial were consistent with the known profile of the medicine.

    • 23 hours ago by Dow Jones
      Companies Mentioned: AMGN

      of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all.

Peers Headlines